Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml Leukaemia
Status:
Withdrawn
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
Non-randomized, multi-centre, open label, uncontrolled, multiple dose, phase IIa study.
A total of 18 patients diagnosed with acute myeloid leukaemia (AML) scheduled for
chemotherapy and expected to be neutropenic (<500 Absolute neutrophil count (ANC)/µl) for >10
days will be treated. F901318 will be given in conjunction with fluconazole or posaconzaole
in order to assess safe treatment regimens for both combinations.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
F2G Biotech GmbH F2G Ltd.
Collaborators:
Klinik für Hämatologie, Aachen Medizinische Klinik Würzburg The Clinical Trials Centre Cologne